minervaneurosciences.com (NERV) - Price-to-Projected Revenue Ratio
Minerva Neurosciences (NERV) is investing in the development of roluperidone small molecules to combat schizophrenia. The forward price-to-sales ratio on the GURU.Markets chart links these developments to future sales of insomnia treatments, where determines the latest valuation metric. Meanwhile, the company strictly adheres to environmental regulations regarding medical waste disposal.
Comprehensive metric breakdowns and analytics for Minerva (NERV)
- stock price and consensus target price:
- market capitalization indicators:
- book value of equity indicators:
- company total debt and liquidity indicators:
Debt to Equity Minerva Neurosciences|NERV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Minerva Neurosciences|NERV - Company Cumulative Debt|Debt to Book Capitalization Ratio Minerva|NERV - Long-Term Debt Volume|Company Short-Term Debts Minerva Neurosciences|Quick Ratio minervaneurosciences.com
- financial results and valuation multiples details:
NERV - Net Financial Result|Projected Future Earnings Minerva Neurosciences|NERV - Market Cap to Earnings|Future Price to Earnings Minerva Neurosciences Corp|NERV - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Minerva|NERV - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Minerva Neurosciences|NERV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months minervaneurosciences.com|NERV - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Minerva Neurosciences
- revenue and sales details:
Initial company analysis:NERV (Minerva Neurosciences, Inc.)
Minerva Neurosciences focuses on developing innovative drugs for the therapy of schizophrenia, leveraging deep expertise in neuroscience. By analyzing the future P/S multiple valuation, an investor can view the ratio of current market capitalization to projected revenue in a real-time assessment, which allows for determining the capital's margin of safety under negative scenarios and evaluating the degree of business discounting relative to expected sales.
Analysis of competing companies
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|RGC - Price-to-Projected Revenue Ratio|AXSM (Axsome Corp) - Market Cap to Projected Revenue|ACAD: Forward P/S Multiple|Market Cap to Future Revenue Ratio xenon-pharma.com (XENE)|Forward Price-to-Revenue Multiple VKTX|Forward P/S Multiple Supernus Pharmaceuticals, Inc.|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Harmony Biosciences HRMY|biohavenpharma.com (BHVN) - Market Cap to Future Revenue Ratio|AMLX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|PRAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Prothena Corporation (PRTA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALEC|ANNX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omeros OMER|NGNE: Market Cap to Projected Revenue|AC Immune - Forward P/S Multiple|voyagertherapeutics.com (VYGR) - Forward Price-to-Revenue Multiple|NMRA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Alpha Cognition Corp (ACOG) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|inhibikase.com - Market Cap to Projected Revenue|Forward P/S Multiple SAVA (Cassava Sciences)|Assertio Holdings (ASRT) - Market Cap to Future Revenue Ratio|COYA - Price-to-Projected Revenue Ratio|Forward Price to Sales VTGN (Vistagen Therapeutics)|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|ABOS (acumenpharm.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio CervoMed|Market Cap to Projected Revenue ATHE (Alterity Therapeutics Ltd)|Forward P/S Multiple CLNN|PEPG - Market Cap to Future Revenue Ratio|Jupiter Neurosciences Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple relmada.com RLMD|ANVS - Price-to-Projected Revenue Ratio|Forward Price to Sales GRCE (Grace Therapeutics, Inc.)|Firefly Neuroscience Inc (AIFF) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Klotho Neurosciences (KLTO)|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|Forward Price-to-Revenue Multiple revivapharma.com (RVPH)|Forward P/S Multiple MTVA|Market Cap to Expected Sales Ratio NeurAxis Inc.|Price-to-Projected Revenue Ratio Helius Medical Technologies HSDT|PASG: Market Cap to Projected Revenue|Neuphoria - Forward P/S Multiple|Market Cap to Future Revenue Ratio athira.com|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|Alzamend Neuro - Forward Price to Sales|Forward Price-to-Revenue Multiple CYCN|Price-to-Projected Revenue Ratio PTIX|Forward P/S Multiple KTTA|Forward P/S Multiple cortigent.com (CRGT)|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales BCLI|CARA - Price-to-Projected Revenue Ratio|CHRO (Chromocell) - Market Cap to Projected Revenue|ELYM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Forward Price-to-Revenue Multiple LBPH|Forward P/S Multiple Marinus Pharmaceuticals Inc|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Vigil Neuroscience VIGL|WENA: Forward P/S Multiple|Forward Price-to-Revenue Multiple Cerevel Corp
